2025
Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE
Kasolowsky V, Gross M, Madoff D, Duncan J, Taddei T, Strazzabosco M, Jaffe A, Chapiro J. Comparison of prognostic accuracy of HCC staging systems in patients undergoing TACE. Clinical Imaging 2025, 120: 110438. PMID: 40049074, DOI: 10.1016/j.clinimag.2025.110438.Peer-Reviewed Original ResearchConceptsOverall survival of patientsBCLC staging systemTransarterial chemoembolizationOverall survivalStaging systemHepatocellular carcinomaStaging systems of hepatocellular carcinomaHepatocellular carcinoma staging systemsRetrospective single center studyKaplan Meier survival analysisInternational Staging SystemSingle center studyLog-rank testTertiary care centerPredicting overall survivalMeier survival analysisConsecutive patientsPrognostic stratificationStudy endpointPrognostic accuracyCenter studyPrognostic powerStratify outcomesMultivariate analysisPatients
2024
Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: the TRANSFORM-HF trial
Nouhravesh N, Clare R, Wojdyla D, Anstrom K, Velazquez E, Greene S, Pitt B, Mentz R, Psotka M. Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: the TRANSFORM-HF trial. European Heart Journal 2024, 45: ehae666.1068. DOI: 10.1093/eurheartj/ehae666.1068.Peer-Reviewed Original ResearchKCCQ-CSSTertile 1Diuretic doseHeart failureAll-cause mortalityTertile 3Tertile 2Diuretic strategyKansas City Cardiomyopathy Questionnaire Clinical Summary ScoreDoses of loop diureticsHigh doses of furosemideComposite all-cause mortalityBaseline to monthDose of furosemideClinical summary scoreRisk of adverse eventsInteraction p valuePost hoc analysisFurosemide equivalentsLoop diureticsOpen-labelMedian ageNo significant differenceClinical outcomesStudy endpointA Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects
Yao F, Wang C, Ding J, Zhang Q, Zheng L, Zhang Q, Yang T, Zhang X, Shan Y, Hou S, Wang H, Zhou R, Hu W. A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects. Drug Design Development And Therapy 2024, 18: 3891-3901. PMID: 39224901, PMCID: PMC11368109, DOI: 10.2147/dddt.s470619.Peer-Reviewed Original ResearchConceptsHealthy Chinese male subjectsChinese male subjectsGeometric mean ratiosAnti-drug antibodiesDouble-blindMale subjectsRates of anti-drug antibodiesPK parametersNon-radiographic axial spondyloarthritisIncidence of TEAEsPhase I studyPrimary study endpointInterleukin (IL)-17AArea under the curveEnthesitis-related arthritisTreatment of psoriasisConfidence intervalsSafety profileSingle doseHidradenitis suppurativaSecukinumabStudy endpointAdverse eventsAxial spondyloarthritisImmunogenicity analysisSecondary interventions following open vs endovascular revascularization for chronic limb threatening ischemia in the BEST-CLI trial
Conte M, Azene E, Doros G, Gasper W, Hamza T, Kashyap V, Guzman R, Mena-Hurtado C, Menard M, Rosenfield K, Rowe V, Strong M, Farber A. Secondary interventions following open vs endovascular revascularization for chronic limb threatening ischemia in the BEST-CLI trial. Journal Of Vascular Surgery 2024, 79: 1428-1437.e4. PMID: 38368997, DOI: 10.1016/j.jvs.2024.02.005.Peer-Reviewed Original ResearchIntention-to-treatBEST-CLIChronic limb-threatening ischemiaOpen bypassRe-interventionBEST-CLI trialCohort 1Limb-threatening ischemiaSecondary analysisCox regression modelsOpen armMultivariate Cox regression modelRegression modelsDuration of follow-upTrial cohortCohortAnalyzed dataRandomized trialsFollow-upReduced hazardEndovascular revascularizationCLTIInitial treatmentTrialsStudy endpoint
2023
Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM
Wong S, Hamidi H, Costa L, Bekri S, Neparidze N, Vij R, Nielsen T, Raval A, Sareen R, Wassner-Fritsch E, Cho H. Multi-omic analysis of the tumor microenvironment shows clinical correlations in Ph1 study of atezolizumab +/- SoC in MM. Frontiers In Immunology 2023, 14: 1085893. PMID: 37559718, PMCID: PMC10408441, DOI: 10.3389/fimmu.2023.1085893.Peer-Reviewed Original ResearchConceptsOverall response ratePatient selection criteriaMultiple myelomaAdverse eventsClinical correlationRelapsed/refractory (R/R) diseaseTumor microenvironmentFuture immunotherapy studiesPhase 1b studyR Multiple MyelomaTreatment-emergent deathsStandard of careBone marrow samplesMulti-omics analysisImmunotherapy studiesRefractory diseaseStudy endpointClinical outcomesAntibody atezolizumabClinical efficacyImmune microenvironmentPatient populationSuch therapyTargeted therapyMarrow samplesThe evolution of lung cancer and impact of subclonal selection in TRACERx
Frankell A, Dietzen M, Al Bakir M, Lim E, Karasaki T, Ward S, Veeriah S, Colliver E, Huebner A, Bunkum A, Hill M, Grigoriadis K, Moore D, Black J, Liu W, Thol K, Pich O, Watkins T, Naceur-Lombardelli C, Cook D, Salgado R, Wilson G, Bailey C, Angelova M, Bentham R, Martínez-Ruiz C, Abbosh C, Nicholson A, Le Quesne J, Biswas D, Rosenthal R, Puttick C, Hessey S, Lee C, Prymas P, Toncheva A, Smith J, Xing W, Nicod J, Price G, Kerr K, Naidu B, Middleton G, Blyth K, Fennell D, Forster M, Lee S, Falzon M, Hewish M, Shackcloth M, Lim E, Benafif S, Russell P, Boleti E, Krebs M, Lester J, Papadatos-Pastos D, Ahmad T, Thakrar R, Lawrence D, Navani N, Janes S, Dive C, Blackhall F, Summers Y, Cave J, Marafioti T, Herrero J, Quezada S, Peggs K, Schwarz R, Van Loo P, Miedema D, Birkbak N, Hiley C, Hackshaw A, Zaccaria S, Jamal-Hanjani M, McGranahan N, Swanton C. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature 2023, 616: 525-533. PMID: 37046096, PMCID: PMC10115649, DOI: 10.1038/s41586-023-05783-5.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerDisease-free survivalCell lung cancerWhole-genome doublingLung cancerLung adenocarcinomaAssociated with shorter disease-free survivalShorter disease-free survivalEvolution of lung cancerPattern of relapseSubclonal selectionPrimary study endpointHistory of smokingSubclonal expansionsCopy number instabilityEGFR mutationsCancer-associated mortalityCopy number heterogeneityClinical outcomesStudy endpointIntratumour heterogeneityNever-smokersClonal expansionFollow-upOncogenic isoformPharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects
Zhang Q, Sun C, Wu J, Wu J, Zhang X, Liu Y, Dou C, Qin H, Zhang Q, Zhou R, Hu W. Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects. Expert Opinion On Biological Therapy 2023, 23: 727-735. PMID: 36880118, DOI: 10.1080/14712598.2023.2189009.Peer-Reviewed Original ResearchConceptsHealthy Chinese male subjectsChinese male subjectsGeometric mean ratiosMale subjectsImmunogenicity profilePK parametersGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsChinese Clinical Trial RegistryCardiovascular adverse eventsParallel-group studyPrimary study endpointClinical Trials RegistryMaximum serum concentrationLast quantifiable concentrationBiosimilar candidateConfidence intervalsConcentration-time curvePK similarityAdverse eventsGlycemic controlStudy endpointTrials RegistryImmunogenicity dataComparable safety
2022
195. Reducing Time to Optimal Antimicrobial Therapy (OAT) for Bloodstream Infections (BSI) due to Gram Positive Cocci (GPC) in Chains Using Rapid Diagnostics Paired with Antimicrobial Stewardship (ASP) Efforts
K J, McSweeney T, McManus D, Davis M, Merwede J, Peaper D, Topal J. 195. Reducing Time to Optimal Antimicrobial Therapy (OAT) for Bloodstream Infections (BSI) due to Gram Positive Cocci (GPC) in Chains Using Rapid Diagnostics Paired with Antimicrobial Stewardship (ASP) Efforts. Open Forum Infectious Diseases 2022, 9: ofac492.273. PMCID: PMC9752006, DOI: 10.1093/ofid/ofac492.273.Peer-Reviewed Original ResearchOptimal antimicrobial therapyLength of stayGram-positive cocciBloodstream infectionsASP recommendationsHigher Charlson comorbidity indexMedian LOSCharlson Comorbidity IndexPost-implementation cohortPre-implementation cohortPrimary study endpointRetrospective chart reviewRapid diagnosticsPositive Gram stainYears of ageAntimicrobial stewardship effortsASP interventionsComorbidity indexPrimary endpointBaseline demographicsChart reviewSecondary outcomesStudy endpointPolymicrobial infectionsAntimicrobial therapyEfficacy and Safety of Sugammadex to Shorten Time-to-Extubation Following Cardiac Surgery: A Single-Center Randomized Placebo-Controlled Trial
Bardia A, Treggiari M, Dai F, Johnson C, Singh M, Kunze K, Tickoo M, Tantawy H, Giersson A, Darr U, Schonberger R. Efficacy and Safety of Sugammadex to Shorten Time-to-Extubation Following Cardiac Surgery: A Single-Center Randomized Placebo-Controlled Trial. Critical Care Explorations 2022, 4: e0821. PMID: 36601562, PMCID: PMC9788969, DOI: 10.1097/cce.0000000000000821.Peer-Reviewed Original ResearchAortic valve replacementCardiac surgeryNeuromuscular blockadeCombined Aortic Valve ReplacementElective aortic valve replacementEfficacy of sugammadexStudy drug administrationCoronary artery bypassPlacebo-controlled trialPrimary study endpointResidual neuromuscular blockadeUse of sugammadexArtery bypassPlacebo groupSugammadex groupBaseline characteristicsValve replacementAnesthetic medicationsStudy endpointMechanical ventilationModifiable factorsCardiothoracic ICUICU settingNMB reversalPatients
2021
A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects
Zhou R, Yang J, Liu Y, Zhang Q, Lu C, Tang K, Li X, Tang W, Gao E, Wu C, Dou C, Hu W. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects. Expert Opinion On Biological Therapy 2021, 22: 263-269. PMID: 34913787, DOI: 10.1080/14712598.2022.2019703.Peer-Reviewed Original ResearchConceptsHealthy Chinese male subjectsChinese male subjectsStudy endpointBevacizumab biosimilarPK parametersMale subjectsGMRs of AUCParallel-group studyPrimary study endpointSecondary study endpointsMaximum serum concentrationLast quantifiable concentrationFurther clinical evaluationConcentration-time curveHealthy Chinese malesInhibitors of angiogenesisAnti-cancer therapyImmunogenicity profileComparable safetySimilar immunogenicitySerum concentrationsClinical evaluationBioequivalence marginTime zeroHealthy subjectsMulticenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma
Weishaar K, Wright Z, Rosenberg M, Post G, McDaniel J, Clifford C, Phillips B, Bergman P, Randall E, Avery A, Thamm D, Hull A, Gust C, Donoghue A. Multicenter, randomized, double‐blinded, placebo‐controlled study of rabacfosadine in dogs with lymphoma. Journal Of Veterinary Internal Medicine 2021, 36: 215-226. PMID: 34952995, PMCID: PMC8783351, DOI: 10.1111/jvim.16341.Peer-Reviewed Original ResearchConceptsBest overall response ratePlacebo-treated dogsProgression-free survivalOverall response rateAdverse eventsResponse rateMedian progression-free survivalCommon adverse eventsPlacebo-controlled studySerious adverse eventsNovel chemotherapy agentsClient-owned dogsTreatment of lymphomaRAB groupSignificant antitumor efficacyStudy endpointMulticentric lymphomaTreatment completionChemotherapy agentsPercent progressionSafety dataLast treatmentClinical importanceLymphomaRabacfosadineSafety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes
Carlson AL, Sherr JL, Shulman DI, Garg SK, Pop-Busui R, Bode BW, Lilenquist DR, Brazg RL, Kaiserman KB, Kipnes MS, Thrasher JR, Reed JHC, Slover RH, Philis-Tsimikas A, Christiansen M, Grosman B, Roy A, Vella M, Jonkers RAM, Chen X, Shin J, Cordero TL, Lee SW, Rhinehart AS, Vigersky RA. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2021, 24: 178-189. PMID: 34694909, PMCID: PMC8971997, DOI: 10.1089/dia.2021.0319.Peer-Reviewed Original ResearchConceptsAdvanced hybrid closed-loop systemMulticenter single-arm studyPredictive low glucose managementDiabetic ketoacidosis eventsSingle-arm studySensor-augmented pumpType 1 diabetesWilcoxon signed-rank testStudy phaseKetoacidosis eventsTreat populationHybrid closed-loop systemMean A1CGlycemic targetsGlucose targetsPivotal trialsStudy endpointGlucose managementGlycemic outcomesSigned-rank testAge groupsStudy participantsType 1Safety eventsA1CUse of Patient-Reported Outcomes Measurement Information System Pediatric Measures as Clinical Trial Endpoints: Experience from a Multicenter Pragmatic Trial in Children with Crohn’s Disease
Miller T, Schuchard J, Carle A, Forrest C, Kappelman M, Group T, Adler J, Ammoury R, Bass D, Bass J, Benkov K, Bousvaros A, Boyle B, Cabrera J, Colletti R, Dorsey J, Ebach D, Firestine A, Gulati A, Hoffenberg E, Jester T, Kaplan J, Kugathasan S, Kusek M, Leibowitz I, Linville T, Margolis P, Minar P, Rios Z, Moses J, Palomo P, Pappa H, Pashankar D, Saeed S, Samson C, Sandberg K, Steiner S, Strople J, Sullivan J, Tung J, Wali P. Use of Patient-Reported Outcomes Measurement Information System Pediatric Measures as Clinical Trial Endpoints: Experience from a Multicenter Pragmatic Trial in Children with Crohn’s Disease. The Journal Of Pediatrics 2021, 242: 86-92.e3. PMID: 34740588, PMCID: PMC8882140, DOI: 10.1016/j.jpeds.2021.10.053.Peer-Reviewed Original ResearchConceptsPROMIS pediatric measuresMulticenter pragmatic trialCrohn's diseasePediatric measuresClinical trialsDisease activityPain interferencePragmatic trialPediatric patient-reported outcome measuresPatient-reported outcome measuresLower PRO scoresOutcomes Measurement Information System (PROMIS) pediatric measuresPRO score changesSteroid-free remissionPediatric Crohn's diseaseChronic pediatric illnessPragmatic clinical trialsClinical trial endpointsUse of patientPediatric patientsStudy endpointClinical outcomesPRO scoresTrial endpointsPRO endpointsAccess to Urologic Care at Urgent Care Centers
Hsiang WR, Yousman L, Kim D, Cavallo JA, Kenney PA, Motamedinia P, Breyer B, Leapman MS. Access to Urologic Care at Urgent Care Centers. Urology 2021, 156: 124-128. PMID: 34181971, DOI: 10.1016/j.urology.2021.06.009.Peer-Reviewed Original ResearchConceptsUrgent care centersUrologic careCare centerCommercial insuranceMultivariable logistic regression analysisPrimary study endpointCross-sectional studyFacility-level characteristicsLogistic regression analysisMedicaid expansion statesLogistic regression modelsState Medicaid expansionsStudy endpointMedicaid insuranceCommercial patientsEmergency departmentReferral ratesPatient insuranceMedicaid patientsUrologic conditionsUrologic emergencyGreater oddsPatientsTriage ratesClinical settingChange in facility-level share of Medicaid patients with cancer following implementation of the affordable care act.
Buck M, Demkowicz P, Nie J, Marks V, Salazar M, Kenney P, Boffa D, Leapman M. Change in facility-level share of Medicaid patients with cancer following implementation of the affordable care act. Journal Of Clinical Oncology 2021, 39: e18543-e18543. DOI: 10.1200/jco.2021.39.15_suppl.e18543.Peer-Reviewed Original ResearchProportion of MedicaidAffordable Care ActMedicaid patientsMedicaid expansionFacility-level changesFacility-level policiesNational Cancer DatabasePrimary study endpointProportion of patientsInsurance coverageMultivariable logistic regressionExpansion statesCare ActFacility-level factorsMedicaid expansion statesNon-expansion statesAdult patientsStudy endpointAdjusted differenceCancer DatabaseMedicaid populationEligible facilitiesPatientsCancerLogistic regressionIntercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure
Fuery MA, Chouairi F, Januzzi JL, Moe GW, Caraballo C, McCullough M, Miller PE, Reinhardt SW, Clark K, Oseran A, Milner A, Pacor J, Kahn PA, Singh A, Ravindra N, Guha A, Vadlamani L, Kulkarni NS, Fiuzat M, Felker GM, O'Connor CM, Ahmad T, Ezekowitz J, Desai NR. Intercountry Differences in Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure. JACC Heart Failure 2021, 9: 497-505. PMID: 33992564, DOI: 10.1016/j.jchf.2021.02.011.Peer-Reviewed Original ResearchConceptsGuideline-directed medical therapyGDMT useCountry of enrollmentHeart failureMedical therapyHigher body mass indexKaplan-Meier survival estimatesGUIDE-IT trialHeart failure hospitalizationReduced ejection fractionLog-rank testingMineralocorticoid receptor antagonistsPrimary study endpointBody mass indexPatterns of careCare delivery structuresGUIDE-ITHF hospitalizationFailure hospitalizationUsual careEjection fractionStudy endpointBlack patientsClinical outcomesMass indexSpot urine sodium in acute heart failure: differences in prognostic value on admission and discharge
Biegus J, Zymliński R, Fudim M, Testani J, Sokolski M, Marciniak D, Ponikowska B, Guzik M, Garus M, Urban S, Ponikowski P. Spot urine sodium in acute heart failure: differences in prognostic value on admission and discharge. ESC Heart Failure 2021, 8: 2597-2602. PMID: 33932273, PMCID: PMC8318409, DOI: 10.1002/ehf2.13372.Peer-Reviewed Original ResearchConceptsHazard ratioComposite endpointAHF rehospitalizationPrognostic significancePrognostic utilityAcute heart failure hospitalizationSpot urine sodiumAcute heart failureHeart failure hospitalizationMortality hazard ratioCourse of hospitalizationConfidence intervalsDifferent prognostic significanceEarly phaseAHF patientsOral furosemideCause mortalityFailure hospitalizationIndex hospitalizationUrine sodiumSodium excretionHeart failureStudy endpointClinical statusPrognostic value
2018
First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology
Kang JJ, Reiter RE, Steinberg ML, King CR. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. European Urology Oncology 2018, 1: 378-385. PMID: 31158076, DOI: 10.1016/j.euo.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedFollow-Up StudiesHumansMaleMargins of ExcisionMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingNeoplasm, ResidualPostoperative PeriodPrognosisProstate-Specific AntigenProstatectomyProstatic NeoplasmsRadiotherapy, AdjuvantRetrospective StudiesRisk FactorsSalvage TherapySurvival AnalysisConceptsBone metastasis-free survivalProstate cancer-specific survivalUltrasensitive prostate specific antigenOverall survivalBiochemical relapseProstate-specific antigenRadical prostatectomyMultivariate analysisProstate-specific antigen levelImmediate adjuvant therapyOccult prostate cancerOccult systemic diseaseCancer-specific survivalEarly salvage radiotherapyHigh-risk diseaseKaplan-Meier methodTraditional risk factorsMetastasis-free survivalPrediction of outcomeProstate cancer pathologyAdjuvant therapySalvage radiotherapyHormone therapyIndependent predictorsStudy endpoint
2017
Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients
Sun JL, Boyle SH, Samad Z, Babyak MA, Wilson JL, Kuhn C, Becker RC, Ortel TL, Williams RB, Rogers JG, O’Connor C, Velazquez EJ, Jiang W. Mental stress-induced left ventricular dysfunction and adverse outcome in ischemic heart disease patients. European Journal Of Preventive Cardiology 2017, 24: 591-599. PMID: 28067532, PMCID: PMC6093615, DOI: 10.1177/2047487316686435.Peer-Reviewed Original ResearchMeSH KeywordsAgedCitalopramDisease-Free SurvivalFemaleHumansMaleMental HealthMiddle AgedMultivariate AnalysisMyocardial IschemiaProportional Hazards ModelsRisk AssessmentRisk FactorsSelective Serotonin Reuptake InhibitorsStress, PsychologicalStroke VolumeTime FactorsTreatment OutcomeVentricular Dysfunction, LeftVentricular Function, LeftConceptsMental stress-induced myocardial ischemiaMajor adverse cardiovascular eventsAdverse cardiovascular eventsLeft ventricular ejection fraction changeVentricular ejection fraction changeStable ischemic heart diseaseIschemic heart disease patientsLeft ventricular ejection fractionStress-induced myocardial ischemiaEjection fraction changesVentricular ejection fractionIschemic heart diseaseCardiovascular eventsHeart disease patientsMyocardial ischemiaEjection fractionStudy endpointDisease patientsHeart diseaseMental Stress–Induced Myocardial IschemiaStress-induced left ventricular dysfunctionFuture adverse cardiovascular eventsLeft ventricular dysfunctionHeart failure statusAssociation of indices
2016
Calcium and 1,25-dihydroxyvitamin D3 modulate genes of immune and inflammatory pathways in the human colon: a human crossover trial 1–3
Protiva P, Pendyala S, Nelson C, Augenlicht LH, Lipkin M, Holt PR. Calcium and 1,25-dihydroxyvitamin D3 modulate genes of immune and inflammatory pathways in the human colon: a human crossover trial 1–3. American Journal Of Clinical Nutrition 2016, 103: 1224-1231. PMID: 27009752, PMCID: PMC4841933, DOI: 10.3945/ajcn.114.105304.Peer-Reviewed Original ResearchConceptsWestern-style dietCalcium supplementationInflammatory pathwaysImmune responseHuman colorectumAdequate vitamin D statusHigh dietary calcium intakeLower colorectal cancer riskClinical trial evidenceDietary calcium intakePrimary study endpointVitamin D statusColorectal cancer riskUrinary calcium concentrationD statusCalcium intakeUrinary calciumStudy endpointCrossover trialTrial evidenceBiopsy specimensColorectal mucosaTrial protocolColonic mucosaAdaptive immunity
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply